GlassScriptPhysician profile
Jeffrey S Holmes
NPI 1982665329
$8,819.75
in general payments reported to CMS, 2019-2025
50 companies · $2,784 in 2025
The $2,784 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $230 · 2021: $222 · 2022: $1,258 · 2023: $1,288 · 2024: $1,778 · 2025: $2,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,064 · Travel and Lodging: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,063.82 |
| Travel and Lodging | $786.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,169.00 | 2022-2025 | Journey II, Tandem, Real Intelligence |
| Novo Nordisk INC | $992.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $818.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $760.50 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $661.17 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $398.91 | 2022-2025 | |
| Dexcom, INC. | $341.36 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $322.55 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.07 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $272.21 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.31 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $250.83 | 2019-2025 | Verquvo, Capvaxive, Gardasil |
| Pfizer INC. | $233.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $195.71 | 2019-2022 | |
| Astellas Pharma US INC | $172.78 | 2019-2023 | Myrbetriq |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.